Constellation Pharmaceuticals Is A Clinical Stage Biopharmaceutical Company Focused On Discovering And Developing Novel Therapeuticsparticularly In The Field Of Epigeneticsacquired By Morphosys In 2021The Company Aims To Enhance Treatment Options In Hematology Oncology And Expand Into Solid Tumors The Company Specializes In Innovative Cancer Treatmentswith Lead Product Candidates Including Pelabresibcpi 0610 A Bet Inhibitor In Phase 3 Trials For Myelofibrosisand Cpi 0209A Second Generation Ezh2 Inhibitor In Phase 2 Trials For Hematological And Solid Tumorsconstellation Also Has A Pipeline Of Preclinical Compoundsfurther Broadening Its Therapeutic Potential
